Clinical Trials
25 trialsNCT01451853 2026-06-03
SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Sound Pharmaceuticals, Incorporated
Phase 2 Withdrawn
NCT03402880 2026-05-29
ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT06682013 2026-05-29
Virtual Agent Feasibility in Oncology Patients (NTT Data)
Duke University
Phase NA Withdrawn
NCT07073183 2026-05-29
Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)
CureVac
Phase 1 Withdrawn
NCT03804255 2026-05-06
Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
Eastern Cooperative Oncology Group
Withdrawn
NCT06732258 2026-04-29
Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
Sichuan University
Phase 1 Withdrawn
NCT07328490 2026-04-28
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT02633514 2026-04-27
Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma
Fudan University
Phase 3 Withdrawn
NCT06572722 2026-04-27
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
Fudan University
Phase 2 Withdrawn
NCT06836414 2026-04-13
Lung Cancer Screening CT for Firefighters
University of California, San Francisco
Phase NA Withdrawn
NCT06434103 2026-04-08
Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Withdrawn
NCT06713798 2026-03-23
INDIGO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT06654050 2026-03-17
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT05566223 2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2 Withdrawn
NCT05488626 2026-02-05
ARTIA-Lung
Varian, a Siemens Healthineers Company
Phase NA Withdrawn
NCT06646016 2025-12-26
EPIC
Therakos LLC
Phase 2 Withdrawn
NCT05472623 2025-09-15
Neo-Kan
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT06746324 2025-09-15
AI-Lung
University of Florida
Withdrawn
NCT00210171 2025-09-10
BIB 01
Institut Bergonié
Phase 2 Withdrawn
NCT06084689 2025-09-02
EMPIRE
Institut Bergonié
Phase 2 Withdrawn
NCT06555263 2025-08-22
Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer
Sutro Biopharma, Inc.
Phase 2 Withdrawn
NCT06676917 2025-08-08
TUXEDO-5
MedSIR
Phase 2 Withdrawn
NCT04615884 2025-07-28
CH:II
Lady Davis Institute
Phase NA Withdrawn
NCT02264236 2025-07-20
Vaccination of Advanced-Stage Lung Cancer Patients
University of Arkansas
Phase 1/2 Withdrawn
NCT05879484 2025-07-10
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn